Island Pharmaceuticals Ltd has released a press release.
ISLA-101 shows anti-dengue activity in Phase 2a readout
Filed with ASX ·
6ix hasn’t read this filing yet.
Island Pharmaceuticals Ltd on 6ix
In the deck
Earlier from Island Pharmaceuticals
- Receipt of R&D tax refund for FY2024
- Clinical trial progress update
- Island completes $3.5m Placement
- Phase 2a PROTECT clinical trial dosed & Investor webinar
- Binding LOI for proposed acquisition of Galidesivir
Later from Island Pharmaceuticals
- US patent granted for ISLA-101
- ISLA-101 Phase 2b clinical trial enrols first subjects
- Completion of enrolment in Phase 2b arm
- Completion of patient dosing in Phase 2b clinical trial
- Phase 2a/b clinical trial update
Follow Island Pharmaceuticals into a list and get an email when it puts out news.
Follow Island Pharmaceuticals